All In Biotech

Drug Trial Radar · NCT05834803

Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients.

Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients - a Danish Nationwide Randomized Sham-Controlled Study.

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jun 26, 2023

Primary completion

Jun 1, 2027

Study completion Jun 1, 2027

Sponsor

Lead sponsor
University of AarhusAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Aarhus University Hospital; Copenhagen University Hospital, Rigshospitalet; Odense University Hospital; Aalborg University Hospital; Gødstrup Hospital; Holbaek Sygehus; Amsterdam UMC; The Augustinus Foundation, Denmark.; Novo Nordisk Foundation
First posted
Apr 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to investigate whether percutaneous transluminal renal angioplasty (PTRA) with stent placement of atherosclerotic renal artery stenosis is beneficial in high-risk patients selected according to the criteria used in the DAN-PTRAI study. The main questions the trial aims to answer are whether renal artery stenting in addition to optimal medical therapy, compared with a sham procedure and optimal medical therapy, has beneficial effects on: * Blood pressure (primary outcome: 24-hour ambulatory systolic blood pressure at 6 months) * Kidney function * Hospitalizations for heart failure

Conditions

  • Renovascular Hypertension
  • Renovascular Hypertension With Renal Failure
  • Heart Failure
  • Renal Artery Stenosis Atherosclerotic

Interventions

  • Optimal medical therapy (OMT)Drug

    Optimal medical therapy, including maximally tolerated renin-angiotensin system blockade with either an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker.

  • Catheter-based angiographyDiagnostic test

    Catheter-based angiography performed in accordance with the study protocol.

  • Measurement of translesional pressure gradientsDiagnostic test

    Measurement of translesional pressure gradients performed in accordance with the study protocol.

  • Renal artery stentingProcedure

    Renal artery stenting performed in accordance with the study protocol.

  • Sham (No Treatment)Procedure

    Sham procedure performed in accordance with the study protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in 24-hour ambulatory systolic blood pressureTime frame: Baseline and 6 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Aarhus University Hospital

    Aarhus N, Denmark · Recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Odense University Hospital

    Odense C, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.